help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunaif, A.
Right arrow Articles by Dobrjansky, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunaif, A.
Right arrow Articles by Dobrjansky, A.

Journal of Clinical Endocrinology & Metabolism, Vol 70, 699-704, Copyright © 1990 by Endocrine Society


ARTICLES

Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome

A Dunaif, G Green, W Futterweit and A Dobrjansky
Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029.

Women with the polycystic ovary syndrome (PCO) have significant insulin resistance and are at risk to develop noninsulin-dependent diabetes mellitus. It remains controversial, however, whether hyperandrogenism directly decreases insulin action. Hence, we performed 2-h euglycemic glucose (approximately 772 pmol/L steady state insulin levels) clamps in nine PCO women with insulin resistance basally and after the 12th week of therapy with a superagonist GnRH analog (40 micrograms every 8 h, sc). Diet, activity, and weight were kept constant. Despite significant decreases in plasma testosterone and androstenedione levels (both P less than 0.05), there was no significant change in insulin- mediated glucose disposal, plasma insulin levels, or hepatic glucose production. The sample size was adequate to detect a clinically significant change in insulin-stimulated glucose disposal (i.e. approximately 3.3 mumol/kg.min; P less than or equal to 0.05). We conclude that suppressing androgen levels into the normal range did not result in significant changes in insulin resistance in PCO. Thus, controlling hyperandrogenemia is not a clinically effective modality to improve insulin action and thereby decrease the risk of noninsulin- dependent diabetes in PCO.


This article has been cited by other articles:


Home page
Hum Reprod UpdateHome page
M.L. Hendriks, J.C.F. Ket, P.G.A. Hompes, R. Homburg, and C.B. Lambalk
Why does ovarian surgery in PCOS help? Insight into the endocrine implications of ovarian surgery for ovulation induction in polycystic ovary syndrome
Hum. Reprod. Update, May 1, 2007; 13(3): 249 - 264.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Codner and H. F. Escobar-Morreale
Hyperandrogenism and Polycystic Ovary Syndrome in Women with Type 1 Diabetes Mellitus
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1209 - 1216.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
A Corbould
Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women
J. Endocrinol., March 1, 2007; 192(3): 585 - 594.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Third Annual World Congress on the Insulin Resistance Syndrome: Associated conditions.
Diabetes Care, September 1, 2006; 29(9): 2165 - 2174.
[Full Text] [PDF]


Home page
Eur J EndocrinolHome page
D. Macut, S. Damjanovic, D. Panidis, N. Spanos, B. Glisic, M. Petakov, D. Rousso, A. Kourtis, J. Bjekic, and N. Milic
Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS.
Eur. J. Endocrinol., July 1, 2006; 155(1): 131 - 136.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
E. Volpi, S. A. Lieberman, D. M. Ferrer, C. R. Gilkison, B. B. Rasmussen, M. Nagamani, and R. J. Urban
The Relationships Between Testosterone, Body Composition, and Insulin Resistance: A lesson from a case of extreme hyperandrogenism
Diabetes Care, February 1, 2005; 28(2): 429 - 432.
[Full Text] [PDF]


Home page
Clin. DiabetesHome page
J. L. Sharpless
Polycystic Ovary Syndrome and the Metabolic Syndrome
Clin. Diabetes, October 1, 2003; 21(4): 154 - 161.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
V. Pylvanen, M. Knip, A. J. Pakarinen, J. Turkka, M. Kotila, J. Rattya, V. V. Myllyla, and J. I.T. Isojarvi
Fasting serum insulin and lipid levels in men with epilepsy
Neurology, February 25, 2003; 60(4): 571 - 574.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Morin-Papunen, I. Vauhkonen, R. Koivunen, A. Ruokonen, H. Martikainen, and J. S. Tapanainen
Metformin Versus Ethinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study
J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 148 - 156.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Andersson, G. Johannsson, G. Holm, B.-A. Bengtsson, A. Sashegyi, I. Pavo, T. Mason, and P. W. Anderson
Raloxifene Does Not Affect Insulin Sensitivity or Glycemic Control in Postmenopausal Women with Type 2 Diabetes Mellitus: A Randomized Clinical Trial
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 122 - 128.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
V.L. Armstrong, M.I. Wiggam, C.N. Ennis, B. Sheridan, A.I. Traub, A.B. Atkinson, and P.M. Bell
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate
QJM, January 1, 2001; 94(1): 31 - 37.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
L. Ibáñez, J. DiMartino-Nardi, N. Potau, and P. Saenger
Premature Adrenarche--Normal Variant or Forerunner of Adult Disease?
Endocr. Rev., December 1, 2000; 21(6): 671 - 696.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
J. W. M. Martens, D. H. Geller, W. Arlt, R. J. Auchus, V. S. Ossovskaya, H. Rodriguez, A. Dunaif, and W. L. Miller
Enzymatic Activities of P450c17 Stably Expressed in Fibroblasts from Patients with the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4338 - 4346.
[Abstract] [Full Text]


Home page
Ann. N. Y. Acad. Sci.Home page
E. DIAMANTI-KANDARAKIS and E. ZAPANTI
Insulin Sensitizers and Antiandrogens in the Treatment of Polycystic Ovary Syndrome
Ann. N.Y. Acad. Sci., April 1, 2000; 900(1): 203 - 212.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. Ciotta, V. De Leo, F. Galvani, A. La Marca, and A. Cianci
Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia
Hum. Reprod., December 1, 1999; 14(12): 2951 - 2958.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Lemieux, G. F. Lewis, A. Ben-Chetrit, G. Steiner, and E. M. Greenblatt
Correction of Hyperandrogenemia by Laparoscopic Ovarian Cautery in Women with Polycystic Ovarian Syndrome Is Not Accompanied by Improved Insulin Sensitivity or Lipid-Lipoprotein Levels
J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4278 - 4282.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice
The Insulin-Related Ovarian Regulatory System in Health and Disease
Endocr. Rev., August 1, 1999; 20(4): 535 - 582.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. Cagnacci, A.M. Paoletti, S. Arangino, G.B. Melis, and A. Volpe
Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism
Hum. Reprod., April 1, 1999; 14(4): 893 - 897.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. P. Diamond, D. Grainger, M. C. Diamond, R. S. Sherwin, and R. A. DeFronzo
Effects of Methyltestosterone on Insulin Secretion and Sensitivity In Women
J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4420 - 4425.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
A. Dunaif
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis
Endocr. Rev., December 1, 1997; 18(6): 774 - 800.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
J. E. Nestler and D. J. Jakubowicz
Lean Women with Polycystic Ovary Syndrome Respond to Insulin Reduction with Decreases in Ovarian P450c17{alpha} Activity and Serum Androgens
J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4075 - 4079.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
I. Ek, P. Arner, A. Bergqvist, K. Carlstrom, and H. Wahrenberg
Impaired Adipocyte Lipolysis in Nonobese Women with the Polycystic Ovary Syndrome: A Possible Link to Insulin Resistance?
J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1147 - 1153.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. B. Phillips, B. H. Pinkernell, and T.-Y. Jing
Relationship Between Serum Sex Hormones and Coronary Artery Disease in Postmenopausal Women
Arterioscler. Thromb. Vasc. Biol., April 1, 1997; 17(4): 695 - 701.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
D. J. Jakubowicz and J. E. Nestler
17{alpha}-Hydroxyprogesterone Responses to Leuprolide and Serum Androgens in Obese Women with and without Polycystic Ovary Syndrome after Dietary Weight Loss
J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 556 - 560.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. Andersson, L.-A. Mattsson, L. Hahn, L. Lapidus, G. Holm, B.-A. Bengtsson, and P. Bjorntorp
Estrogen Replacement Therapy Decreases Hyperandrogenicity and Improves Glucose Homeostasis and Plasma Lipids in Postmenopausal Women With Noninsulin-Dependent Diabetes Mellitus
J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 638 - 643.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. E. Nestler and D. J. Jakubowicz
Decreases in Ovarian Cytochrome P450c17{alpha} Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary Syndrome
N. Engl. J. Med., August 29, 1996; 335(9): 617 - 623.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. Franks
Polycystic Ovary Syndrome
N. Engl. J. Med., September 28, 1995; 333(13): 853 - 861.
[Full Text] [PDF]


Home page
Reproductive SciencesHome page
E. Diamanti-Kandarakis, G. Tolis, and A. J. Duleba
Androgens and Therapeutic Aspects of Antiandrogens in Women
Reproductive Sciences, July 1, 1995; 2(4): 577 - 592.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society